Physician profile
Aaron Hasiuk
NPI 1417937400
$998.11
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $242 · 2021: $115.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $460.50 | 2019-2021 | |
| Roche Diagnostics Corporation | $113.80 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $106.33 | 2019-2021 | |
| Therapeuticsmd, INC. | $76.99 | 2019-2020 | |
| Amgen INC. | $60.55 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $53.82 | 2019 | |
| Merck Sharp & Dohme LLC | $40.10 | 2019-2020 | |
| Allergan, INC. | $17.65 | 2019 | |
| Pfizer INC. | $14.52 | 2019 | |
| Avion Pharmaceuticals | $14.49 | 2021 | |
| Medicem INC. | $13.95 | 2021 | |
| Evofem Biosciences, INC. | $12.76 | 2021 | |
| Covidien LP | $12.65 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Hasiuk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.